item management s discussion and analysis of financial condition and results of operations note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
overview bio reference has expanded its laboratory testing capabilities and its customer base through internal growth as well as through the completion of a series of acquisitions of the businesses of other testing laboratories 
in april  the company acquired the assets and certain liabilities of medilabs  inc mli for a purchase price of  cash plus a promissory note of  payable without interest  in three semi annual installments commencing april of also in april  the company entered into a note agreement to borrow the  to fund this acquisition 
the note is in accordance with the company s revolving loan agreement with the same lending bank 
the operations of mli are included in the company s operations commencing april  mli incurred a net loss of approximately  for the seven month period ended october  and had net income of approximately  for the twelve month period ended october  in december of  the company entered into agreements to acquire the businesses of two companies 
one company is involved in website designs and the other company is involved in the manufacturing of health care foods 
results of operations net income the company s net income loss for the years ended october  and was  and  respectively 
the main reasons for the  decrease in net income is the write down of approximately  for impaired assets including the additional allowance for accounts receivable relating to the company s end stage renal dialysis business acquired from smithkline beecham of approximately  and an increase in general and administrative expenses of approximately  in fiscal 
in addition  net revenue per patient decreased during the current twelve month period ended october   as compared to the twelve month period ended october  gross profit margins decreased from for the twelve month period ended october  to for the twelve month period ended october  based upon anticipated increases in patient volume  anticipated increased testing to be performed  reimbursement rate improvements  and anticipated decreases in operating costs  the bulk of the effects of which are expected to be realized in the second half of fiscal  the company projects net income for fiscal net revenues net revenues for the year ended october  were  as compared to  for the year ended october   this represents a increase in net revenues 
mli had net revenues of  or of the company s net revenues for the fiscal year 
the company acquired mli in april of  for the seven month period ended october   mli had net revenues of  or of the company s net revenue for the twelve month period ended october  the number of patients serviced during the fiscal year ended october  was  which was greater when compared to the prior fiscal year 
mli accounted for of the patient count for the year ended october  net revenue per patient for the year ended october  was compared to net revenue per patient for the year ended october  of  a reduction of or 
this decrease is due to the inclusion of a full twelve months of mli s revenues with its associated lower revenue per patient in fiscal year mli s net revenue per patient was for the twelve month period ended october  compared to net revenue per patient of in fiscal year the company expects an increase in net revenues in fiscal year due to a number of factors internal growth  an estimated increase in the contract with the new york state department of corrections  medicare reimbursement for tests previously not covered  an increase in medicare reimbursement for other selected tests  as well as new marketing initiatives in newer testing areas  such as drugs of abuse testing  and complimentary and alternative medicine 
in addition  the company has identified three new business initiatives see below  all of which seek to leverage off existing capabilities the company possesses 
the company anticipates increasing its revenues in its next fiscal year through internal growth and development of new marketing initiatives in laboratory testing services outside the traditional physician market 
in november  the contract to provide laboratory testing by the new york state department of corrections for inmates in its facilities was renewed 
this contract is valued at approximately  for fiscal year  an estimated increase of approximately from fiscal year the company is seeking to market its services to other correctional institutions 
in june  the company announced the signing of a letter of intent with general prescription programs  inc  a prescription benefit manager gpp and others  to form a new company  called psimedica  which will provide population health management and medical claims processing services to third party payors of health related claims and benefits 
the new company  principally funded by brli  is expected to obtain a license to market medical management services to gpp customers representing approximately one million lives 
the license will also provide the new company with access to gpp s claims information and analytical software 
the company believes  through the analytical process of interrelating laboratory  prescription and medical claims data  it can provide critical strategies and solutions to promote population health management primarily to erisa funds and other payors 
no assurances can be given that the company will be able to successfully market these strategies and solutions 
in  the company licensed software to allow for the grouping of the analysis of medical claims data and has proceeded to develop its own proprietary algorithms and enhancements to the licensed software so as to include laboratory and prescription data 
the company is currently negotiating with two erisa funds which total over  lives as beta sites for its analytical tools and programs 
the company expects to seek customers for its services by mid fiscal year in december  the company announced the acquisition of doctorny 
com www 
doctorny 
com  a health portal which  with its associated domain sites and existing physician websites  includes website development capabilities for health care providers  together with a search engine which allows consumers to locate physicians by region  credentials  specialty or other parameters 
the company announced the consumer view represented by doctorny 
com was part of its entry into the e health marketplace 
the company plans to further develop the physician services offered by the system to enhance physician patient and physician payor electronic communications on a secure basis ie  preserving confidentiality  including communicating laboratory results  e mail prescriptions  refills  payor verification and eligibility  etc 
the offering of physician cme credits through the system is also contemplated 
the company intends to market these services to its existing physician network as well as to other individual physicians and groups of physicians 
in december  the company acquired right body foods  inc  a manufacturer and distributor of freshly prepared  starch free  low calorie  low carbohydrate  food products  located in syosset  new york 
its products are sold through health professionals  dieticians  nutritionists and physicians 
the company expects to use its marketing staff and physician network to increase the distribution of these products 
cost of services cost of sales increased from  for the year ended october  to  for the year ended october   an increase of  or 
this increase is primarily the result of the mli acquisition 
mli s direct operating costs were  for the twelve month period ended october   as compared to  for the seven month period ended october   an increase of  the optimum consolidation of laboratory operations has not been completed and will marginally impact the company s cost structure until  at least  the second quarter of fiscal year when the automated laboratory upgrade and expansion is expected to be completed 
while the automated laboratory will have a marginal impact on cost structure  the reduction of the company s dependence on reference laboratories is expected to have a more favorable impact during the second half of fiscal gross profits gross profit on net revenues increased from  for the year ended october  to  for the year ended october   an increase of  primarily attributable to the increase in revenues 
gross profit margins decreased from for the year ended october  to for the year ended october  management believes that the company s gross profit margin will increase in fiscal  due to increased revenues from internal growth  medicare reimbursement for tests not previously covered  increases in reimbursement rates from medicare on certain tests  the completion of the automated chemistry laboratory and decrease in direct operating expenses 
the decrease in gross profit margins in fiscal is primarily attributable to the lower net revenues per patient  the increase in direct costs associated with mli and the duplication of direct costs that had not been eliminated as of october  by an optimum consolidation of laboratory operations 
the company has invested a large amount of time and money during fiscal to increase its processing capacity 
management believes  that its capacity once the automated chemistry laboratory is completed  for approximately  will be more than adequate to handle the projected increase in patient volume 
note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
general and administrative expenses general and administrative expenses for the year ended october  were  as compared to  for the year ended october   an increase of approximately  or 
approximately of this increase is the impairment charge of approximately  associated with the company s end stage renal dialysis business acquired from smithkline beecham 
in addition  occupancy expenses  telephone  data processing and marketing expenses increased approximately  over the prior twelve month period 
the company recorded a  expense associated with a new jersey medicaid overpayment claim 
management believes that general and administrative expenses in will increase but not at a higher percentage than the projected increase in revenues 
interest expense interest expense increased from  for the year ended october  to  for the year ended october   resulting from the company s continuing use of its revolving line of credit with pnc bank 
fiscal year compared to fiscal year net income the company s net income for the years ended october  and was  and  respectively 
the main reasons for the  decrease in net income is the reduction in nonrecurring gain of approximately  the nonrecurring gain represents the gain in the sale of certain assets of the company s gencare division 
the reduction in income from operations resulted from a reduced gross profit percentage of approximately and an increase in general and administrative expenses 
net revenues on september   the company completed the sale of certain assets of its gencare division gencare to an unrelated third party 
gencare provided largely cancer diagnostic testing services with relatively high revenues per patient 
the financial statements included eleven months of revenues attributable to the gencare division or  there were no revenues realized by the gencare division in net revenues for the year ended october  were  as compared to  for the year ended october   this represents a increase in net revenues 
the company acquired mli in april of since this acquisition  for the seven month period ended october   mli had net revenues of  or of the company s net revenues for the year 
there were no revenues from mli in fiscal mli provides routine laboratory services to physician offices  clinics  nursing homes and correctional institutions  associated with lower revenues per patient 
the number of patients serviced during the year ended october  was  which was greater when compared to the prior fiscal year 
mli accounted for of the patient count for the year ended october  net revenue per patient for the year ended october  was compared to net revenue per patient for the year ended october  of  a reduction of or 
mli s net revenue per patient was for the seven month period ended october  the company anticipated increasing its revenues in its next fiscal year through internal growth and development of new marketing initiatives in laboratory testing services outside the traditional physician market 
in april  the company acquired mli and was awarded  as of november   a contract to provide laboratory testing by the new york state department of corrections for inmates in its note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
facilities 
the company is seeking to market its services to other correctional institutions 
in addition  the company is attempting to expand its marketing efforts in the drug testing market and has hired new marketing representatives to specialize in this initiative 
cost of services cost of sales increased from  for the year ended october  to  for the year ended october   an increase of  or 
this increase is the result of the mli acquisition 
mli s direct operating costs were  for the seven month period ended october  the optimum consolidation of laboratory operations has not been completed and will impact the company s cost structure until completed 
gross profits gross profit on net revenues increased from  for the year ended october  to  for the year ended october   an increase of  primarily attributable to the increase in revenues 
gross profit margins decreased from for the year ended october  to for the year ended october  this decrease in gross profit margins is primarily attributable to the lower net revenues per patient  the increase in direct costs associated with mli and the duplication of direct costs that had not been eliminated as of october  by an optimum consolidation of laboratory operations 
general and administrative expenses general and administrative expenses for the year ended october  were  as compared to  for the year ended october   an increase of approximately  or 
most of this increase was due to the incurring of additional costs related to the mli acquisition approximately 
in addition  bad debt increased by  or approximately  over the prior comparable period and was caused primarily by an increase in the self pay patients of bio reference laboratories resulting from legislation passed in new jersey which prohibited physician billing for diagnostic laboratory services 
self pay patients have an historical higher bad debt rate than that of physician billing 
interest expense interest expense increased from  for the year ended october  to  for the year ended october   resulting from the company s increase in asset based borrowing of approximately  and acquisition debt of  offset by payments on existing debt of  liquidity and capital resources for the fiscal year ended october  the company s working capital at october  was approximately  as compared to approximately  at october   a decrease of  this change is primarily the result of a decrease in accounts receivable of approximately  an increase in accounts payable and accrued expenses of approximately  and the utilization of cash to decrease long term debt of approximately  the company reduced its debt through the utilization of its restricted certificates of deposit 
this allowed the company to realize a cost savings on the spread between the interest earned on these certificates of deposit and the interest expense on the monies borrowed 
during the year ended october   the company generated approximately  in cash from operations  an increase of approximately  as compared to the year ended october each operating unit of clinical laboratory testing services generated cash flow during the period ended note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
october  mli  the company s most recent laboratory acquisition generated approximately  in cash from operating activities and bio reference generated approximately  corporate activities general and administrative expenses utilized approximately  in cash during the twelve month period ended october  the company expects cash flow from operations to continue to improve during fiscal overall  management anticipates being able to generate cash from operations in fiscal as a result of a projected increased gross profit resulting from increased revenues and a projected decrease in operating costs 
management believes operating costs will be lower due to cost savings generated by the automated laboratory and cost reductions generated by doing certain large volume laboratory tests in house rather than referring them to another laboratory 
credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base 
the company does have significant receivable balances with government payors and various insurance carriers 
generally  the company does not require collateral or other security to support customer receivables  however  the company continually monitors and evaluates its client acceptance and collection procedures to minimize potential credit risks associated with its accounts receivable 
the company establishes and maintains an allowance for uncollectible accounts based upon collection history and anticipated collection  and as a consequence  believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements 
a number of proposals for legislation continue to be under discussion which could substantially reduce medicare and medicaid reimbursements to clinical laboratories 
depending upon the nature of regulatory action  and the content of legislation  the company could experience a significant decrease in revenues from medicare and medicaid  which could have a material adverse effect on the company 
medicare has announced that it will more than double the reimbursement rate for pap tests from to and reimburse for psa tests starting january  the company is unable to predict  however  the extent to which other such actions will be taken 
see developments since the beginning of fiscal as to the status of a review concerning overpayments being conducted by the company s medicare carrier and new jersey medicaid 
in january  the company commenced negotiations with new jersey medicaid regarding a claim the claim made by the state in december that with respect to certain clinical laboratory tests for which reimbursements were made by the state to the company  although such tests were authorized by the physician  the underlying laboratory test requisitions did not bear the actual signature of the physician ordering the test 
the company believes it has been compliant with all requirements regarding claims submitted for payment by new jersey medicaid and in fact require actual physician signatures before it bills new jersey medicaid 
however  the company and new jersey medicaid have entered into an oral agreement in january to a settlement of approximately  to cover the claim and the company has accrued this settlement amount in its october  financial statements 
the settlement is subject to the parties execution of a written agreement setting forth its terms and to the approval of the director of the division of medical assistance 
approval of the settlement is being recommended to the director 
new jersey medicaid is the only payor the company does business with that requires an actual physician signature on every laboratory requisition 
in the fiscal year ending october   new jersey medicaid represented approximately of the company s total net revenues 
in april  the company amended its revolving loan agreement with pnc bank 
the maximum amount of the credit line available to the company is the lesser of  or ii of the company s qualified accounts receivable 
as defined in the agreement 
plus of any face amount of the certificates of deposit  if any  pledged as collateral for this loan minus the amount of any portion of the outstanding principal balance of the term loan which is deemed to be collateralized by the certificates of deposit 
interest on advances which are collateralized by certificates of deposit will be at above the certificate of deposit interest rate 
interest on other advances will be at prime plus 
the credit line note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
is collateralized by substantially all of the company s assets and the assignment of a  insurance policy on the life of the president of the company 
the line of credit is available through march and may be extended for annual periods by mutual consent thereafter 
the terms of this agreement contain  among other provisions  requirements for maintaining defined levels of capital expenditures and net worth  various financial ratios and insurance coverage 
as of october   the company was in compliance with the covenant provisions of this agreement and was utilizing  of this credit facility 
as of october   the company was in default of certain covenants  however  the company subsequently received waivers for these defaults on january  as of october   the company was utilizing  of this credit facility 
the company generated approximately  of positive cash flow from operating and investing activities for the year ended october   which was applied toward payments totaling approximately  to reduce short and long term debt and capital lease obligations 
the company intends to expand its laboratory operations through acquisitions and aggressive marketing while also diversifying into related medical fields through acquisitions 
these acquisitions may involve cash  notes  common stock  and or combinations thereof the company has various employment and consulting agreements of up to seven years with commitments totaling approximately  
see notes and and operating leases with commitments totaling approximately  of which approximately  and  are due during fiscal 
see note 
the company s cash balances at october  totaled approximately  as compared to  at october  the company believes that its cash position  the anticipated cash generated from future operations  the availability of its credit line with pnc bank  the utilization of certificates of deposits maturing during the second quarter of fiscal year and the interest due thereupon  will meet its future cash needs 
for the fiscal year ended october  working capital at october  was approximately  as compared to approximately  at october   a decrease of  during the twelve month period 
in fiscal year  the company utilized  in cash for operating activities 
this use of cash for operating activities resulted in an increase in accounts receivable of approximately  offset by the increase in accrued expenses and payables of approximately  the company utilized  of cash for investing activities during fiscal year this consisted primarily of  of cash paid for medilabs 
impact of inflation to date  inflation has not had a material effect on the company s operations 
new authoritative pronouncements the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 accounting for derivative instruments and hedging activities deferral of effective date of fasb statements no 
the statement defers for one year the effective date of fasb statement no 
 accounting for derivative instruments and hedging activities 
the rule now will apply to all fiscal quarters of all fiscal years beginning after june  the statement will require the company to recognize all derivatives on the balance sheet at fair value 
derivatives that are not hedges must be adjusted to fair value through income 
if the derivative is a hedge  depending on the value of the hedged assets  liabilities  or firm commitments through earnings or recognized in other note regarding forward looking statements this annual report on form k contains historical information as well as forward looking statements 
statements looking forward in time are included in this annual report pursuant to the safe harbor provisions of the private securities litigation reform act of such statements involve known and unknown risks and uncertainties that may cause the company s actual results in future periods to be materially different from any future performance suggested herein 
comprehensive income until the hedged item is recognized in earnings 
the ineffective portion of a derivative s change in fair value will be immediately recognized in earnings 
the adoption of sfas no 
is not expected to have a material impact on the company s consolidated results of operation  financial position or cash flows 
item a 
quantitative and qualitative disclosure about market risk not applicable 

